Skip to main content
Premium Trial:

Request an Annual Quote

Something New: Oct 20, 2011

Harvard Medical School has launched a new program, the Initiative in Systems Pharmacology, which In the Pipeline's Derek Lowe describes as "a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one." Harvard says the new initiative is part of the medical school's Program in Translational Science and Therapeutics, and that its two main goals are to increase researchers' knowledge of human disease mechanisms, and to more effectively translate their ideas, "improving the quality of drug candidates as they enter the clinical testing and regulatory approval process." But while this is all "worthy stuff," Lowe says, there still remain a few questions — what are the drug candidates that Harvard wants to improve the quality of, and how might they be picked? Lowe says the effort is certainly worth it, and that the researchers at Harvard are certainly up to the challenge. But, he adds, "it's also worth remembering Harvard's approach to licensing and industrial collaboration. Let's just say that they didn't get that endowment up to its present size by letting much slip through their fingers."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.